Latest Ratios: P/E Ratio 19.8x · EV/EBITDA 16.9x · ROE 14.9%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $93.2B | $83.8B | $82.0B | $99.9B | $81.9B | $70.9B | $55.6B | $43.0B | $42.9B | $43.6B | $42.7B |
| Enterprise Value | $92.8B | $83.4B | $82.2B | $99.8B | $81.5B | $70.7B | $56.1B | $42.1B | $42.1B | $43.5B | $42.6B |
| P/E Ratio → | 19.82 | 18.61 | 18.58 | 25.26 | 18.88 | 8.77 | 15.83 | 20.34 | 17.54 | 36.36 | 47.67 |
| P/S Ratio | 5.51 | 5.84 | 5.77 | 7.61 | 6.73 | 4.41 | 6.54 | 6.56 | 6.39 | 7.42 | 8.78 |
| P/B Ratio | 3.14 | 2.68 | 2.79 | 3.84 | 3.61 | 3.78 | 5.04 | 3.88 | 4.90 | 7.09 | 9.60 |
| P/FCF | 25.97 | 20.54 | 22.37 | 27.23 | 18.51 | 10.85 | 27.75 | 21.51 | 23.66 | 42.12 | 43.83 |
| P/OCF | 18.71 | 16.84 | 18.55 | 21.74 | 16.33 | 10.01 | 21.24 | 17.71 | 19.53 | 33.34 | 28.73 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.82 | 5.79 | 7.61 | 6.69 | 4.40 | 6.60 | 6.42 | 6.28 | 7.40 | 8.77 |
| EV / EBITDA | 16.85 | 20.24 | 18.38 | 20.93 | 14.23 | 7.65 | 14.72 | 17.41 | 15.70 | 19.54 | 29.70 |
| EV / EBIT | 25.92 | 15.81 | 17.00 | 23.37 | 16.57 | 7.53 | 14.51 | 17.13 | 16.31 | 20.66 | 31.89 |
| EV / FCF | — | 20.44 | 22.43 | 27.22 | 18.42 | 10.82 | 28.00 | 21.06 | 23.24 | 42.02 | 43.78 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.4% | 85.4% | 86.1% | 82.9% | 86.0% | 83.1% | 84.0% | 85.1% | 91.3% | 90.8% | 91.7% |
| Operating Margin | 24.9% | 24.9% | 28.1% | 33.2% | 44.2% | 55.7% | 42.1% | 33.7% | 37.8% | 35.4% | 27.4% |
| Net Profit Margin | 31.4% | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% | 32.3% | 36.4% | 20.4% | 18.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 14.9% | 14.9% | 16.0% | 16.3% | 20.9% | 54.2% | 31.8% | 21.3% | 32.8% | 22.6% | 22.1% |
| ROA | 11.5% | 11.5% | 12.5% | 12.7% | 15.9% | 37.9% | 22.0% | 15.9% | 23.8% | 15.2% | 14.2% |
| ROIC | 8.9% | 8.9% | 10.8% | 13.5% | 19.8% | 44.6% | 24.7% | 18.2% | 27.1% | 29.9% | 26.2% |
| ROCE | 10.2% | 10.2% | 12.6% | 15.6% | 22.6% | 49.7% | 26.3% | 19.2% | 28.3% | 31.1% | 25.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.09 | 0.10 | 0.12 | 0.14 | 0.24 | 0.06 | 0.08 | 0.11 | 0.11 |
| Debt / EBITDA | 0.66 | 0.66 | 0.60 | 0.57 | 0.47 | 0.29 | 0.71 | 0.29 | 0.26 | 0.32 | 0.34 |
| Net Debt / Equity | — | -0.01 | 0.01 | -0.00 | -0.02 | -0.01 | 0.05 | -0.08 | -0.09 | -0.02 | -0.01 |
| Net Debt / EBITDA | -0.10 | -0.10 | 0.05 | -0.01 | -0.07 | -0.02 | 0.13 | -0.37 | -0.28 | -0.05 | -0.04 |
| Debt / FCF | — | -0.10 | 0.06 | -0.01 | -0.09 | -0.03 | 0.25 | -0.45 | -0.42 | -0.11 | -0.06 |
| Interest Coverage | 120.42 | 120.42 | 87.59 | 58.52 | 82.80 | 163.75 | 67.97 | 81.43 | 91.55 | 83.75 | 185.82 |
Net cash position: cash ($3.1B) exceeds total debt ($2.7B)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.13 | 4.13 | 4.73 | 5.69 | 5.06 | 3.56 | 3.63 | 3.67 | 5.52 | 4.93 | 3.15 |
| Quick Ratio | 3.39 | 3.39 | 3.95 | 4.94 | 4.29 | 3.07 | 2.91 | 2.99 | 4.72 | 4.29 | 2.83 |
| Cash Ratio | 1.97 | 1.97 | 2.28 | 3.17 | 2.46 | 1.45 | 1.33 | 1.53 | 1.95 | 1.24 | 0.84 |
| Asset Turnover | — | 0.35 | 0.38 | 0.40 | 0.42 | 0.63 | 0.50 | 0.44 | 0.57 | 0.67 | 0.70 |
| Inventory Turnover | 0.66 | 0.66 | 0.64 | 0.87 | 0.71 | 1.40 | 0.71 | 0.69 | 0.51 | 0.75 | 1.01 |
| Days Sales Outstanding | — | 146.10 | 159.65 | 157.70 | 159.78 | 137.09 | 176.75 | 155.05 | 122.01 | 122.72 | 121.03 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.4% | 0.4% | — | — | — | — | — | — | — | — | — |
| Payout Ratio | 8.2% | 8.2% | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.0% | 5.4% | 5.4% | 4.0% | 5.3% | 11.4% | 6.3% | 4.9% | 5.7% | 2.8% | 2.1% |
| FCF Yield | 3.9% | 4.9% | 4.5% | 3.7% | 5.4% | 9.2% | 3.6% | 4.6% | 4.2% | 2.4% | 2.3% |
| Buyback Yield | 4.3% | 4.7% | 4.4% | 2.2% | 3.1% | 3.8% | 11.7% | 1.1% | 0.4% | 0.7% | 0.3% |
| Total Shareholder Yield | 4.6% | 5.2% | 4.4% | 2.2% | 3.1% | 3.8% | 11.7% | 1.1% | 0.4% | 0.7% | 0.3% |
| Shares Outstanding | — | $109M | $115M | $114M | $114M | $112M | $115M | $115M | $115M | $116M | $116M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying REGN stock.
Regeneron Pharmaceuticals, Inc.'s current P/E ratio is 19.8x. The historical average is 38.4x. This places it at the 47th percentile of its historical range.
Regeneron Pharmaceuticals, Inc.'s current EV/EBITDA is 16.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 25.8x.
Regeneron Pharmaceuticals, Inc.'s return on equity (ROE) is 14.9%. The historical average is -3.0%.
Based on historical data, Regeneron Pharmaceuticals, Inc. is trading at a P/E of 19.8x. This is at the 47th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Regeneron Pharmaceuticals, Inc.'s current dividend yield is 0.38% with a payout ratio of 8.2%.
Regeneron Pharmaceuticals, Inc. has 85.4% gross margin and 24.9% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Regeneron Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 0.7x, indicating low leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Lumpy earnings and cash timing
Metrics are mathematically derived from official filings.
Trailing Multiples Look Full, Forward Discount Narrows
Based on the supplied valuation data, REGN trades at 21.77 trailing P/E and 22.47 EV/EBITDA, which compares with a 15.06 forward P/E, implying the market expects earnings to recover from the trailing base rather than extend it.
The gap between trailing and forward P/E suggests investors are pricing in sustained earnings growth, though the PEG of 3.44 indicates that growth expectations are already priced at a premium. Against peers such as VRTX at 35.41 P/E and INCY at 18.41, REGN appears moderately valued, but this comparison depends heavily on whether the recent quarterly margin expansion proves durable. Investors should monitor whether forward estimates hold given the uneven revenue history.
Margin Expansion Driven by Mix, Not Consistency
According to the reported ratio data, REGN's operating margin moved from 19.5% in 2025Q1 to 40.0% in 2026Q3, while net margin ranged from 20.2% to 40.4% across the ten quarters, showing wide quarterly dispersion.
The 2026Q3 operating margin of 40.0% sits well above the 17.8% low in 2026Q1, suggesting that high-margin revenue mix or favorable cost timing drove the latest expansion rather than a steady structural improvement. Net margin exceeding operating margin in several quarters points to non-operating contributions that warrant further investigation before treating reported earnings as recurring earning power. The trailing data alone does not establish whether the current margin level is sustainable.
Returns Oscillate Without a Clear Compounding Trend
Based on the supplied quarterly data, ROIC ranged from 1.5% in 2025Q1 to 4.8% in 2026Q3, and ROE from 2.3% to 6.0%, both remaining low relative to the 23.0% ROIC reported by VRTX and 51.1% by INCY.
Returns on invested capital remain modest for a company with a 6.5 to 8 figure equity base, which suggests that the large retained earnings and asset base are not yet generating proportional economic profit. The recent improvement in ROIC from its early-period trough is encouraging but has not yet established a sustained upward path. Compared with peers, REGN's capital efficiency appears structurally lower, though the gap may narrow if margin gains persist.
Liquidity Cushion Narrowing but Still Comfortable
As reported in financial statements, REGN's current ratio fell from 5.44 in 2024Q2 to 3.35 in 2026Q3 and quick ratio from 4.62 to 2.89, which still leaves a substantial margin above the 1.0 threshold commonly used for near-term obligations.
The steady decline in current ratio reflects growing current liabilities relative to current assets, which may indicate rising operating obligations or the deployment of cash into buybacks. Even under stress, the quick ratio near 2.9 suggests that liquid assets excluding inventory comfortably cover current liabilities. The trajectory warrants monitoring, but the absolute level does not suggest near-term liquidity strain.
Low Leverage Flatters Cash Resilience Assessment
Based on reported figures, REGN's debt-to-equity of roughly 0.08 and interest coverage above 200x in recent quarters may make the balance sheet appear stronger than the lumpy free cash flow margin, which ranged from 4.0% to 37.8%, would support.
Low leverage ratios can obscure the fact that cash generation has been erratic, and share repurchases have often absorbed most of the free cash flow produced. The most commonly misapplied metric for a biotechnology company with this profile is EV/EBITDA, since R&D spending and milestone timing can distort EBITDA materially from period to period. Investors should consider free cash flow and R&D-adjusted earnings as a more reliable gauge of earning power than the headline multiple.